MDNR vs MDMA, explained
Class A non-sterile, non-measuring devices can list in the MDNR in about four working days — everything else needs a full MDMA, with the SFDA's official review timeline of 35 working days.
Free field guide · PDF
What manufacturers need to know before entering the Gulf's largest healthcare market — the MDMA pathway, the mandatory Authorized Representative, and the fast lane for low-risk devices.
Sourced from SFDA guidance and 2026 regulatory analyses.
Enter your work email and we'll send the PDF straight to your inbox.
What's inside
Every figure in this guide traces to a named source — SFDA guidance and 2026 regulatory analyses.
Class A non-sterile, non-measuring devices can list in the MDNR in about four working days — everything else needs a full MDMA, with the SFDA's official review timeline of 35 working days.
No foreign manufacturer files directly: an SFDA-licensed Authorized Representative is mandatory for all classes A–D, with a legalized agreement and roughly SAR 2,600/year in license fees.
What the technical file must contain, why reference-market approvals move faster, and the post-market reality: MDEL licensing, NCMDR reporting, and 3-year renewals.
This guide is market-access intelligence, not legal or regulatory advice. Regulatory requirements change — professional review is required before business use.
Market Access Strategy Session
A Market Access Strategy Session maps your product's real registration pathway, timeline, and distributor landscape.
Professional review is required before business use.
Back to ghmap.io Questions? Talk to our team